AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03565068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background AAP Therapy
Description: Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
Study NCT03118284 — intervention group
Intervention type: OTHER
Intervention: urine collection
Study NCT03118284 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Study NCT03118284 — intervention group
Intervention type: BEHAVIORAL
Intervention: NRS
Study NCT01949688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402 or A*0201 restricted peptides
Description: Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.
Study NCT01454635 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: dosage,frequency and duration
Study NCT02261584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Thermal Coagulation
Description: Microwave thermal coagulation of splenic parenchyma.
Study NCT02261584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial Splenic Embolization
Description: Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
Study NCT01226914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVICEL
Description: EVICEL
Study NCT01226914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EVICEL
Description: EVICEL
Study NCT01231139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
Study NCT01231139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Schedule:
Description: Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
Study NCT00722384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib
Study NCT00722384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib
Description: The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
Study NCT02458001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFFRON stepped care
Description: Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)
Study NCT03626532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc.
Study NCT03626532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Education (LifeEd)
Description: This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 250 mg
Description: EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 500 mg
Description: Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.
Study NCT03489018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study NCT03489018 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study NCT03308591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NACT
Description: Platin based chemotherapy
Study NCT03308591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RT+PLND
Description: radical hysterectomy+pelvic lymphadenectomy
Study NCT03308591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RT+PLND
Description: radical hysterectomy+pelvic lymphadenectomy
Study NCT03308591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Platin based chemotherapy
Study NCT03308591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Platin based chemotherapy
Study NCT05500638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
Study NCT04065451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine in the submucosal injection fluid
Study NCT01095978 — intervention group
Intervention type: DRUG
Intervention: Clarithromycin (Klacid SR)
Description: Klacid SR in a dose of 1000 mg once daily
Study NCT04502225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt
Description: Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
Study NCT04502225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated trunk
Description: Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
Study NCT04502225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt - In home
Description: Tilt of the whole bed so that the head is elevated by 8 inches overnight.
Study NCT04502225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated Trunk - In home
Description: Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
Study NCT02287285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin9
Description: Dosed at 600 pmol/kg/min for 210 minutes.
Study NCT02342197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: half the dose of Gn agonist
Study NCT02578121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
Study NCT02578121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4.0 mg will be given on days 1-21 of a 28 day cycle
Study NCT02578121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 750 mg
Description: EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797 1000 mg
Description: Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.
Study NCT01008475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent.
Study NCT04236921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DopaSnap®
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
Study NCT04236921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RDL of CD-LD
Description: (immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
Study NCT02301156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion
Study NCT02301156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally
Study NCT02301156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally
Study NCT04195880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions to Reduce Acute Care Transfers
Description: Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
Study NCT04075617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic habit reminder
Description: Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
Study NCT04075617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: palatal crib
Description: Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
Study NCT01512446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg per week
Study NCT01512446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per week
Study NCT04183582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well
Study NCT01657266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-155
Description: Pre-medication (before surgery) and maintenance treatment.
Study NCT01657266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevanac
Description: Pre-medication (before surgery) and maintenance treatment.
Study NCT03629652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-down position treatment
Description: In the head-down position, the body is in the supine position with the head lowered to 30 degrees
Study NCT03629652 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Rehabilitation
Description: The body is in the supine position without lowered head
Study NCT03629652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: The body is in the supine position without lowered head
Study NCT04366726 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Description: Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
Study NCT00457639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholic Acid
Description: Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
Study NCT00457639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholic Acid
Description: Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
Study NCT02733783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold dry air machine
Description: Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
Study NCT03666884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
Study NCT03666884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS 50% eye drops 8*1
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
Study NCT03944044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol
Description: Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
Study NCT03557216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
Study NCT02929225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifid Triple Viable Capsules
Description: BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
Study NCT02929225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo is also prescribed as a dose of 4 capsules twice daily
Study NCT01395654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid, rifampin, pyrazinamide
Description: rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
Study NCT03323580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDFT
Description: Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone Capsules 30 mg once daily for up to 84 weeks
Study NCT01183013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg / Pioglitazone 45 mg FDC
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
Study NCT03323580 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional fluid therapy
Description: Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
Study NCT03760263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.